Newron Announces Positive Results for Ralfinamide

Newron Announces Positive Results for Ralfinamide

Newron Pharmaceuticals SpA, announced positive preclinical study results showing that ralfinamide has statistically significant benefits against spontaneous chronic pain in an experimental model of central pain. Ralfinamide has shown positive results in chronic pain on CNS targets, in addition to its known peripheral mechanisms; Ralfinamide’s unique ability to affect central targets widens its broad spectrum of analgesic mechanisms, supporting its therapeutic potential for alleviating Neuropathic Low Back Pain (NLBP) in the ongoing SERENA Phase IIb/III clinical trial. The new data also suggest that ralfinamide may be effective in central pain syndromes.

Read the release.